Publications by authors named "Austin Doyle"

Claim this Profile
C
Corrigendum to: LTBK-01. Updates On The Phase Ii And Re-treatment Study Of AZD6244 (Selumetinib) For Children With Recurrent Or Refractory Pediatric Low Grade Glioma: A Pediatric Brain Tumor Consortium (PBTC) Study.
Jason R Fangusaro, Arzu Onar-Thomas, Tina Young Poussaint, Shengjie Wu, Azra H Ligon, L Austin Doyle

Neuro Oncol· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I study of cediranib, an oral VEGFR inhibitor, in combination with selumetinib, an oral MEK inhibitor, in patients with advanced solid malignancies.
Joleen M Hubbard, Jun Yin, Erin L Schenk, Rui Qin, Joel M Reid, L Austin Doyle

Invest New Drugs· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of Capivasertib in Patients With an AKT1 E17K-Mutated Tumor: NCI-MATCH Subprotocol EAY131-Y Nonrandomized Trial.
Kevin Kalinsky, Fangxin Hong, Carolyn K McCourt, Jasgit C Sachdev, Edith P Mitchell, L Austin Doyle

JAMA Oncol· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase I Study of Dinaciclib in Combination With MK-2206 in Patients With Advanced Pancreatic Cancer.
Adrian G Murphy, Marianna Zahurak, Mirat Shah, Colin D Weekes, Aaron Hansen, L Austin Doyle

Clin Transl Sci· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II, 2-stage, 2-arm, PIK3CA mutation stratified trial of MK-2206 in recurrent endometrial cancer.
Andrea P Myers, Panagiotis A Konstantinopoulos, William T Barry, Weixiu Luo, Russell R Broaddus, Austin Doyle

Int J Cancer· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trial.
Panagiotis A Konstantinopoulos, Su-Chun Cheng, Andrea E Wahner Hendrickson, Richard T Penson, Susan T Schumer, L Austin Doyle

Lancet Oncol· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Results of an abbreviated phase II study of AKT inhibitor MK-2206 in the treatment of recurrent platinum-resistant high grade serous ovarian, fallopian tube, or primary peritoneal carcinoma (NCT 01283035).
Elizabeth K Lee, Zhenying Tan-Wasielewski, Carol Aghajanian, Robert L Coleman, Jennifer Curtis, L Austin Doyle

Gynecol Oncol Rep· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Selumetinib in Children with Inoperable Plexiform Neurofibromas.
Andrea M Gross, Pamela L Wolters, Eva Dombi, Andrea Baldwin, Patricia Whitcomb, L Austin Doyle

N Engl J Med· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation.
Yan Xing, Nancy U Lin, Matthew A Maurer, Huiqin Chen, Armeen Mahvash, L Austin Doyle

Breast Cancer Res· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Final results of a randomized multicenter phase II study of alvocidib, cytarabine, and mitoxantrone versus cytarabine and daunorubicin (7 + 3) in newly diagnosed high-risk acute myeloid leukemia (AML).
Joshua F Zeidner, Matthew C Foster, Amanda L Blackford, Mark R Litzow, Lawrence E Morris, L Austin Doyle

Leuk Res· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
University of Chicago phase II consortium trial of selumetinib (MEKi) demonstrates low tolerability and efficacy in relapsed DLBCL.
Natalie Galanina, Sonali M Smith, Chuanhong Liao, Adam Petrich, Bernadette Libao, Austin Doyle

Br J Haematol· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
LC-MS/MS assay for the quantitation of the ATR kinase inhibitor VX-970 in human plasma.
Brian F Kiesel, Jonas Scemama, Robert A Parise, Liza Villaruz, Andre Iffland, Austin Doyle

J Pharm Biomed Anal· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized phase II trial of cytosine arabinoside with and without the CHK1 inhibitor MK-8776 in relapsed and refractory acute myeloid leukemia.
Jonathan A Webster, Raoul Tibes, Larry Morris, Amanda L Blackford, Mark Litzow, L Austin Doyle

Leuk Res· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exposure-Response Analysis of Alvocidib (Flavopiridol) Treatment by Bolus or Hybrid Administration in Newly Diagnosed or Relapsed/Refractory Acute Leukemia Patients.
Carl LaCerte, Vijay Ivaturi, Joga Gobburu, Jacqueline M Greer, L Austin Doyle

Clin Cancer Res· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of Selumetinib and MK-2206 vs Oxaliplatin and Fluorouracil in Patients With Metastatic Pancreatic Cancer After Prior Therapy: SWOG S1115 Study Randomized Clinical Trial.
Vincent Chung, Shannon McDonough, Philip A Philip, Dana Cardin, Andrea Wang-Gillam, L Austin Doyle

JAMA Oncol· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Relationship between physician-adjudicated adverse events and patient-reported health-related quality of life in a phase II clinical trial (NCT01143402) of patients with metastatic uveal melanoma.
Thomas M Atkinson, Jennifer L Hay, Alexander Shoushtari, Yuelin Li, Daniel J Paucar, Austin Doyle

J Cancer Res Clin Oncol· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas.
Eva Dombi, Andrea Baldwin, Leigh J Marcus, Michael J Fisher, Brian Weiss, Austin L Doyle

N Engl J Med· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase I Study of the AKT Inhibitor MK-2206 in Combination with Hormonal Therapy in Postmenopausal Women with Estrogen Receptor-Positive Metastatic Breast Cancer.
Cynthia X Ma, Cesar Sanchez, Feng Gao, Robert Crowder, Michael Naughton, Austin Doyle

Clin Cancer Res· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I study of selumetinib (AZD6244/ARRY-142866), a MEK1/2 inhibitor, in combination with cetuximab in refractory solid tumors and KRAS mutant colorectal cancer.
Dustin A Deming, Ludmila L Cavalcante, Sam J Lubner, Daniel L Mulkerin, Noelle K LoConte, Austin G Doyle

Invest New Drugs· April 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase II Trial of AZD6244 (Selumetinib, ARRY-142886), an Oral MEK1/2 Inhibitor, in Relapsed/Refractory Multiple Myeloma.
Beata Holkova, Adriana Zingone, Maciej Kmieciak, Prithviraj Bose, Ashraf Z Badros, Austin Doyle

Clin Cancer Res· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized multicenter phase II study of flavopiridol (alvocidib), cytarabine, and mitoxantrone (FLAM) versus cytarabine/daunorubicin (7+3) in newly diagnosed acute myeloid leukemia.
Joshua F Zeidner, Matthew C Foster, Amanda L Blackford, Mark R Litzow, Lawrence E Morris, L Austin Doyle

Haematologica· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Results of an abbreviated phase-II study with the Akt Inhibitor MK-2206 in Patients with Advanced Biliary Cancer.
Daniel H Ahn, Junan Li, Lai Wei, Austin Doyle, John L Marshall

Sci Rep· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biomarker-driven phase 2 study of MK-2206 and selumetinib (AZD6244, ARRY-142886) in patients with colorectal cancer.
Khanh Do, Giovanna Speranza, Rachel Bishop, Sonny Khin, Larry Rubinstein, L Austin Doyle

Invest New Drugs· June 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase I Study of Cixutumumab (IMC-A12) in Combination with Temsirolimus (CCI-779) in Children with Recurrent Solid Tumors: A Children's Oncology Group Phase I Consortium Report.
Maryam Fouladi, John P Perentesis, Lars M Wagner, Alexander A Vinks, Joel M Reid, L Austin Doyle

Clin Cancer Res· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Molecular profiling and targeted therapy for advanced thoracic malignancies: a biomarker-derived, multiarm, multihistology phase II basket trial.
Ariel Lopez-Chavez, Anish Thomas, Arun Rajan, Mark Raffeld, Betsy Morrow, Austin Doyle

J Clin Oncol· March 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis